The UK and US have announced a major commercial pact that will guarantee no import taxes on UK medicine exports going into the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has agreed to boost expenditure on pharmaceuticals through the public health system. This pledge guarantees that duties on these key products will be held at zero for a duration of three years.
This agreement is in response to recent statements to hike import taxes on branded drug imports, with figures discussed up to one hundred percent.
"This agreement between the UK bolsters the international landscape for innovative medicines and introduces long-overdue balance to transatlantic medicine commerce," a statement said.
Commercial Significance
Drugs constitute one of the the United Kingdom's most significant exports to the America, which is by far the biggest market for major companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period leading up to September, the UK shipped medicines totaling over eleven billion pounds to the US. This value made up nearly one-fifth of total UK exports in that period.
"This guarantee safeguards jobs, stimulates capital expenditure and paves the way for the UK to emerge as a global hub for biotech and pharma," a government official commented.
Key UK Commitments
The agreement entails several notable commitments from the United Kingdom:
- Price Threshold Increase: The UK will lift the price threshold at which it judges new treatments to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a target to raise overall public funding on medicines from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount drug companies must return to the NHS to prevent overspending will be restricted at 15%. Previously, refunds were more than 20%.
Broader Context
This agreement follows a long-running dispute between the drug companies and the British authorities over drug pricing and regulatory access.
This friction were heightened by arguments that US patients were paying significantly more for the same drugs than people in the UK and Europe.
Recently, several major drug company projects in the UK have been delayed or cancelled, while multi-billion-dollar investments have been directed toward projects in the United States.
A senior figure stated that the NHS needed to invest a greater share on drugs, noting that its budget allocation on drugs had declined as a percentage of its resources over the last ten years.